Edwards Lifesciences (EW) Tops Q2 EPS by 2c, Guides Above for FY08 Revenues
More News related to EW
- First Transcatheter Valve Cases in Japan Performed With Edwards SAPIEN Valve
- Edwards Lifesciences to Present at the Credit Suisse Annual Healthcare Conference
- Edwards Lifesciences (EW) and DexCom (DXCM) Annouce Receipt of CE Mark
- Edwards Lifesciences and DexCom Announce Receipt of CE Mark for Glucose Monitoring System
- Goldman Sachs Ups Edwards Lifesciences (EW) to Buy, On Product Cycle and Possible Take-Out; NUVA Downgraded
More News related to Earnings
- Ocean Bio-Chem (OBCI) Posts Q3 EPS of $0.07, Lower Y/Y by 1c; Revs Higher
- Highlights From CLWR's Q3 Conference Call: Funding Initiative A Go!, But Investors Worry About Long-Term Outlook
- Arden Group (ARDNA) Posts Q3 EPS of $1.48, Beats Q308 by 18c
- Macy's (M) Shows Good Progress, But Not Good Enough
- Universal Security (UUU) Share Trade Higher on Q2 Earnings Report
Edwards Lifesciences (NYSE: EW) reports Q2 EPS of $0.66 (ex-items), 2 cents better than the analyst estimate of $0.64. Revenues for the quarter were $327.6 million, versus the consensus of $311.93 million.
Edwards is raising the midpoint of its 2008 sales guidance by $25 million to between $1.24 billion and $1.28 billion. This revised range reflects strength across all product lines. (Consensus is $1.23 billion)
"We estimate that third quarter 2008 diluted EPS will be between $0.53 and $0.57. We are increasing our full year estimate by $0.05, to between $2.50 and $2.58 per diluted share, excluding special items, which represents a 2008 growth rate of approximately 20%." (Q3 EPS consensus is $0.56 and FY08 EPS consensus is $2.50)
Edwards Lifesciences Corporation provides products and technologies designed to treat cardiovascular diseases.
Related Categories
EarningsGuidance
Stocks Mentioned
+0.02Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
